Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q702 + Azacitidine + Venetoclax in R/R AML
NCT06445907Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adrixetinib in acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Feb 2025; status: active, not recruiting.
02
Drugs
adrixetinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06445907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445907.